Strategic Partnership Collaborate with EMIT Imaging to leverage their Cryo-Fluorescence Tomography CFT capabilities for preclinical drug development programs, offering joint service packages to accelerate biodistribution studies and co-localization analyses for new therapeutics.

High Value Offering Position EMIT’s Xerra™ system and CFT services as a premium, high-resolution solution for whole-body drug distribution and six-plex co-localization, targeting biotech and pharma companies needing advanced biodistribution data for IND-enabling studies.

Strategic Fit Target partners in oncology and biologics research where collaboration with MIT Koch Institute projects could unlock access to cutting-edge cryo-fluorescence capabilities, enhancing credibility and access to leading academic partnerships.

Growth Narrative Capitalize on recent funding developments and leadership expansion by presenting scalable service contracts and instrument-as-a-service options to mid-sized biotech firms seeking robust preclinical imaging without capital expenditure.

Market Positioning Differentiate EMIT Imaging from larger incumbents by emphasizing niche specialization in CFT, ex vivo volumetric tissue imaging, and rapid, global service delivery, appealing to startups and growth-stage companies needing flexible engagement terms.